<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <Volume-Issue>Volume 3; Issue 3</Volume-Issue>
      <Season>(May-Jun, 2022)</Season>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Treatment Intervention of Chronic Plantar Wart Using Gardasil 9 Vaccine - A Case Report</ArticleTitle>
      <Abstract>A case report on the regression of a hyperkeratotic chronic plantar wart, upon administration of the Gardasil 9 vaccine, is presented herein. A 42-year-old patient visited the clinic from September 2020 to May 2021, with symptoms and presentation typical of plantar wart, which contributed to severe disability while walking. The treatment prescribed was liquid nitrogen cryotherapy, curettage and topical salicylic acid. Over 7 months, the wart regressed along with severe treatment-associated inflammation, only to reappear. Gardasil 9 is administered free to secondary school children in Australia as part of the National Immunisation Program Schedule. The patient was a recent migrant and was not immunized, hence requested to be immunized. After a single dose, the patient experienced fever, shedding of wart tissue and surrounding skin. Complete healing took place within 2-3 weeks. It is thus proposed that Gardasil 9 be administered to migrants, and that it may also be considered for use as a therapeutic agent in chronic plantar warts. This may reduce the morbidity period, prevent autoinoculation, viral shedding and community spread.</Abstract>
      <Keywords>Plantar Wart,HPV,Gardasil 9,Treatment</Keywords>
        <Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=13902&amp;title=Treatment Intervention of Chronic Plantar Wart Using Gardasil 9 Vaccine - A Case Report</Abstract>
        <References>Abeck D, Folster-Holst R. Quadrivalent human papillomavirus vaccination: a promising treatment for recalcitrant cutaneous warts in children. Acta Derm Venereol 2015; 95: 1017–1019.&#13;
Al-Awadhi R, Al-Mutairi N, Chehadeh W. Prevalence of HPV Genotypes in Adult Male Patients with Cutaneous Warts: A Cross-Sectional Study. Med Princ Pract 2020; 29: 458–464.&#13;
Boda D, Docea A, Calina D, Ilie M, Caruntu C, Zurac S, Neagu M, Constantin C, Branisteanu D, Voiculescu V, Mamoulakis C, Tzanakakis G, Spandidos D, Drakoulis N and; Tsatsakis A. Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review). Int J Oncol 2018; 52: 637-655.&#13;
Bruggink SC, Gussekloo J, de Koning MN, Feltkamp MC, Bavinck JN, Quint WG, Assendelft WJ, Eekhof JA. HPV type in plantar warts influences natural course and treatment response: secondary analysis of a randomised controlled trial. J Clin Virol 2013; 57: 227-232.&#13;
Daniel BS, Murrell DF. Complete resolution of chronic multiple verruca vulgaris treated with quadrivalent human papillomavirus vaccine. JAMA Dermatol 2013; 149: 370–372.&#13;
Garcand;iacute;a-Oreja S, and;Aacute;lvaro-Afonso FJ, Sevillano-Fernand;aacute;ndez D, Tardand;aacute;guila-Garcand;iacute;a A, Land;oacute;pez-Moral M, Land;aacute;zaro-Martand;iacute;nez JL. A non-invasive method for diagnosing plantar warts caused by human papillomavirus (HPV). J Med Virol 2022; 94: 2897–2901.&#13;
Grussendorf EI. Lichtmikroskopische Untersuchungen an typisierten Viruswarzen (HPV-1 und HPV-4) [Light-microscopic study of classified virus warts (HPV-1 and HPV-4) (authorand;#39;s transl)]. Arch Dermatol Res 1980; 268: 141-148.&#13;
Landini MM, Borgogna C, Peretti A, Doorbar J, Griffin H, Mignone F, et al. Identification of the skin virome in a boy with widespread human papillomavirus-2-positive warts that completely regressed after administration of tetravalent human papillomavirus vaccine. Br J Dermatol 2015; 173: 597–600.&#13;
Landis MN, Lookingbill DP, Sluzevich JC. Recalcitrant plantar warts treated with recombinant quadrivalent human papillomavirus vaccine. J Am Acad Dermatol 2012; 67: e73–e74.&#13;
Lipke MM. An Armamentarium of Wart Treatments. Clin Med Res 2006; 4: 273–293&#13;
MBS Online (n.d.), Medicare Benefits Schedule, Australian Government, Department of Health. http://www9.health.gov.au/mbs/fullDisplay.cfm?type=itemand;q=30189and;qt=item&#13;
Munk-Madsen ZM, Toft L, Kube T, Richter R, Ostergaard L, Sand;oslash;gaard OS, Tolstrup M, Kaufmann AM. Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection. Hum Vaccin Immunother 2018; 14: 909–916.&#13;
Pattyn J, Van Keer S, Tjalma W, Matheeussen V, Van Damme P, Vorsters A. Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature. Papillomavirus Res 2019; 8: 100185.&#13;
TGA. Australian Public Assessment Report for Gardasil, TGA. (2011). [PDF], page 3. https://www.tga.gov.au/sites/default/files/auspargardasil.pdf&#13;
Witchey DJ, Witchey NB, Roth-Kauffman MM, Kauffman MK. Plantar Warts: Epidemiology, Pathophysiology, and Clinical Management. J Am Osteopath Assoc 2018; 118: 92-105.</References>